COVID-19 associated pediatric vasculitis: A systematic review and detailed analysis of the pathogenesisCOVID-19 관련 소아 혈관염: 병인에 대한 체계적인 검토 및 상세 분석Review Published on 2022-08-012022-09-12 Journal: Seminars in arthritis and rheumatism [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] age Analysis Arthritis article caused Central nervous system chilblain children clinical feature Coronavirus disease 2019 Corticosteroid COVID-19 criteria Cyclophosphamide Diagnosis died English Evidence Final IgA immunosuppressive drugs Inflammatory inflammatory complication majority manifestation median age MIS-C Pathogenesis Patient patients patients with COVID-19 pediatric Pediatric vasculitis phenotype Remission renal rheumatology SARS-CoV-2 secure skin subtype syndrome systematic review the patient Treatment Vasculitis was performed were excluded with COVID-19 [DOI] 10.1016/j.semarthrit.2022.152047 PMC 바로가기 [Article Type] Review
Characteristics of our hypoxemic COVID-19 pneumonia patients receiving corticosteroids and mortality-associated factorsMulticenter Study Published on 2022-08-012023-07-10 Journal: Expert review of respiratory medicine [Category] COVID19(2023년), [키워드] Corticosteroid COVID-19 Hypoxemia Mortality Prognosis [DOI] 10.1080/17476348.2022.2102480 [Article Type] Multicenter Study
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysisCOVID-19로 병원에 입원한 환자의 바리시티닙(RECOVERY): 무작위, 통제, 공개 라벨, 플랫폼 시험 및 업데이트된 메타 분석Meta-Analysis Published on 2022-07-302022-09-11 Journal: Lancet (London, England) [Category] COVID19(2023년), SARS, 임상, [키워드] 1:1 28-day mortality 95% CI age-adjusted rate ratio allocation Baricitinib benefit by mouth cause Corticosteroid Corticosteroids COVID-19 COVID-19 therapy death deaths died discharge eight enrolled evaluate Evidence hospital hospitalised Including Infection inhibitor Innovation intention-to-treat population ISRCTN Jak JAK inhibitor jak inhibitors janus Janus kinase Medical Research Council Meta-analysis mouth nine Non-COVID-19 once daily Open-label outcomes Patient Platform trial Primary outcome Proportional reduction randomisation randomised randomised controlled trial Randomised Evaluation Randomly randomly assigned patient rate ratio receive receiving recorded recovery RECOVERY trial reduce mortality reduced reduction in mortality Registered risk of death significantly Standard of care suggested thrombosis Tocilizumab Treatment Trial trials usual care usual care alone usual care group was done with COVID-19 [DOI] 10.1016/S0140-6736(22)01109-6 PMC 바로가기 [Article Type] Meta-Analysis
Multidrug-Resistant Klebsiella pneumoniae in a Patient with SARS-Cov-2 Pneumonia in an Intensive Care Unit in Guayaquil, Ecuador: A Case Report에콰도르 Guayaquil의 중환자실에서 SARS-Cov-2 폐렴 환자의 다제내성 Klebsiella pneumoniae: 증례 보고Case Reports Published on 2022-07-222022-09-11 Journal: The American journal of case reports [Category] COVID19(2023년), SARS, 치료기술, [키워드] Admission admitted to ICU antibiotic Antibiotics Bacterial Blood blood culture broad-spectrum antibiotic carbapenem case study Chain Reaction Chest computed tomography Comorbidities Computed tomography Corticosteroid corticosteroid treatments Corticosteroids COVID-19 COVID-19 pandemic Culture Department Dyspnea Emergency emergency department ESBL health problem ICU ICUs incidence increase in intensive care unit intensive care units intravenously Invasive mechanical ventilation Klebsiella Klebsiella pneumoniae Klebsiella pneumoniae carbapenemase KPC Laboratory management medical history meropenem microorganism multidrug-resistant Nasopharyngeal swab NDM New past medical history pathogen Pathogens Patient polymerase chain polymerase chain reaction positive public health pulmonary infiltrate report reported reverse transcription risk factor Risk factors RT-PCR SARS-CoV2 secretion strain superinfection Swab tracheal Treatment use of corticosteroids vancomycin [DOI] 10.12659/AJCR.936498 PMC 바로가기 [Article Type] Case Reports
Multisystem Inflammatory Syndrome Associated With COVID-19 in Children (MIS-C): A Systematic Review of Studies From India어린이의 COVID-19와 관련된 다기관 염증 증후군(MIS-C): 인도 연구의 체계적인 검토Article Published on 2022-07-152022-09-11 Journal: Indian pediatrics [Category] COVID19(2023년), MERS, SARS, 바이오마커, [키워드] Admissions age article calculate children clinical Clinical features coronavirus disease Coronavirus disease 2019 Corticosteroid Corticosteroids Course COVID-19 database databases derangement disease course disease status Effect feature Features Fever Frequency Future gastrointestinal problem gastrointestinal problems GraphPad GraphPad software Health Organization Immunoglobulin India Inflammatory Inflammatory marker inflammatory markers intensive care Intravenous immunoglobulin IQR Kawasaki disease laboratory parameter Laboratory parameters majority male median MIS-C mortality rate NIH parameter Patient patients ranged reported required review SARS-COV-2 infection Screening Standard deviation syndrome systematic review the disease the mean Therapeutics Treatment was done was used World Health Organization [DOI] 10.1007/s13312-022-2559-5 PMC 바로가기 [Article Type] Article
Clinical, laboratory data and inflammatory biomarkers at baseline as early discharge predictors in hospitalized SARS-CoV-2 infected patients입원한 SARS-CoV-2 감염 환자의 조기 퇴원 예측인자로 기준선에서의 임상, 실험실 데이터 및 염증성 바이오마커Article Published on 2022-07-142022-09-11 Journal: PLoS ONE [Category] COVID19(2023년), MERS, SARS, 바이오마커, [키워드] Admission AUC baseline Beta C-reactive protein category CD25 clinical collected Corticosteroid Corticosteroids cytokine Cytokines D-dimers dehydrogenase Determination discharge discharged Factor group help hospital Hospitalization Hospitalized hospitals identify IMPROVE independent Inflammatory Inflammatory biomarker interferon interleukin laboratory data laboratory parameter Lactate lactate dehydrogenase logistic regression models Macrophage Male sex Mild mild patient mild patients Negative predictive value neutrophil NLR not need NPV oxygen oxygen saturation Oxygen therapy Patient performed plasma plasma sample plasma samples Positive predictive value PPV predict Predictive Predictive value predictor pro-inflammatory cytokine pro-inflammatory cytokines Protein receptor Regression model SARS-CoV-2 infected patient SARS-COV-2 infection SARS-CoV-2 pandemic sensitivity severity Spanish specificity Transmission Treatment variable virus worsening [DOI] 10.1371/journal.pone.0269875 PMC 바로가기 [Article Type] Article
Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalised patients with COVID-19: A network meta-analysis코로나19로 입원한 환자에서 토실리주맙, 사릴루맙, 28일 후 모든 원인 사망률 사이의 연관성: 네트워크 메타 분석Meta-Analysis Published on 2022-07-082022-09-11 Journal: PLoS ONE [Category] meta-analysis, 임상, 진단, [키워드] 28-day mortality all-cause mortality antagonist association choice clinician Consistency Corticosteroid Corticosteroids COVID-19 patient deaths demonstrated dependent on Effect eligible patient Evidence hospitalised patient Hospitalised patients in-hospital mortality inconsistency initiated interleukin-6 interleukin-6 receptor invasive ventilation Meta-analysis Network meta-analysis Non-invasive not dependent Odds ratio Odds ratios P-value Patient Placebo randomisation randomised randomised comparison receiving receptor antagonist REMAP-CAP REMAP-CAP trial sarilumab Tocilizumab Trial usual care Ventilation with COVID-19 [DOI] 10.1371/journal.pone.0270668 PMC 바로가기 [Article Type] Meta-Analysis
SARS-CoV-2 infection in kidney transplant recipients: clinical impact and outcomes – a single center experienceArticle Published on 2022-07-012022-11-15 Journal: J Bras Nefrol [Category] COVID19(2023년), SARS, 치료제, [키워드] adjusted AKI analyzed Antiviral baseline characteristics Clinical features clinical impact Cohort Corticosteroid corticosteroid therapy corticosteroide Corticosteroides Critical died disease severity dose English form General population grave greater higher risk Hospital admission hospitalized patient hospitalized patients ICU Immunosuppression infecção Infection inhibitor IQR kidney transplant kidney transplant recipient management median age Mortality mTOR inhibitor occurred outcome Outpatient outpatients pacientes hospitalizado Pacientes hospitalizados Patient performed Prospective Study prospectivo reached recipient reduction renal required respiratory SARS-CoV-2 SARS-COV-2 infection single center subgroup of patient Treatment UTI Withdrawal [DOI] 10.1590/2175-8239-JBN-2021-0164 PMC 바로가기
Effect of Tocilizumab, Sarilumab, and Baricitinib on Mortality Among Patients Hospitalized for COVID-19 Treated with Corticosteroids: A Systematic Review and Meta-AnalysisReview article Published on 2022-07-012022-10-05 Journal: Clinical microbiology and infection : the official [Category] 임상, [키워드] aggregate all-cause mortality average Baricitinib Bayesian Bia certainty of evidence Cochrane Library Controlled trial Corticosteroid Corticosteroids COVID-19 Effect eligibility criteria Evidence greater Hospitalized hospitalized COVID-19 hospitalized COVID-19 patients margin medRxiv Meta-analysis meta-regression moderate Mortality objective Odds ratio outcome participant Patient patients treated Placebo Probability ranged RCT receiving reduction reductions in required Result review risk of bia sarilumab Standard of care Tocilizumab treated Treatment were used with COVID-19 [DOI] 10.1016/j.cmi.2022.07.008 [Article Type] Review article
Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic임상 실습의 최근 발전: COVID-19 대유행 중 염증성 장 질환 관리Review Published on 2022-07-012022-09-11 Journal: Gut [Category] COVID19(2023년), SARS, 치료기술, [키워드] acquisition adverse outcome adverse outcomes antibody booster dose bowel Breakthrough infection breakthrough infections Cancer cancers Corticosteroid Corticosteroids COVID-19 COVID-19 in patient COVID-19 pandemic Crohn's disease de novo decrease develop diagnoses disease course dose Evidence Future General population Guidance hospitalisation hospitalisations Humoral response humoral responses IBD immune immune response immunosuppressive therapies immunosuppressive therapy increased risk Inflammatory Inflammatory bowel disease management medication medications Necrosis outcome outcomes pandemic Patient patients potential risk primary dose raised receive recent remained Research risk risk of COVID-19 SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 vaccines TNF treated Treatment ulcerative ulcerative colitis Vaccine vaccine response Vaccines [DOI] 10.1136/gutjnl-2021-326784 PMC 바로가기 [Article Type] Review